Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) price closed higher on Monday, September 13, jumping 1.20% above its previous close.
A look at the daily price movement shows that the last close reads $1.66, with intraday deals fluctuated between $1.66 and $1.75. The company’s 5Y monthly beta was ticking 1.18. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.85 and 52-week low of $1.36. The stock added 11.26% on its value in the past month.
Hepion Pharmaceuticals Inc., which has a market valuation of $131.16 million. Analysts tracking HEPA have forecast the quarterly EPS to shrink by 0 per share this quarter, while the same analysts predict the annual EPS to hit -$0.36 for the year 2021 and up to -$0.56 for 2022. In this case, analysts estimate an annual EPS growth of 82.90% for the year and -55.60% for the next year.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give HEPA a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 1 analysts have assigned HEPA a recommendation rating as follows: 0 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Hepion Pharmaceuticals Inc. (HEPA) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that HEPA’s price is at present 8.28% off the SMA20 and 4.27% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 57.81, with weekly volatility standing at 8.73%. The indicator jumps to 5.66% when calculated based on the past 30 days. Hepion Pharmaceuticals Inc. (NASDAQ:HEPA)’s beta value is holding at 1.16, while the average true range (ATR) indicator is currently reading 0.09. Considering analysts have assigned the stock a price target range of $5.00-$5.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $5.00. Based on this estimate, we see that current price is roughly -197.62% off the estimated low and -197.62% off the forecast high. Investors will no doubt be excited to see the share price fall to $5.00, which is the median consensus price, and at that level HEPA would be -197.62% from current price.
An analysis of the Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) stock in terms of its daily trading volume indicates that the 3-month average is 1.86 million.
Current records show that the company has 76.22M in outstanding shares. The insiders’ percentage holdings are 0.14% of outstanding shares while the percentage share held by institutions stands at 21.50%. But the -23.29% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.